secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0001140361-23-030856
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant reports positive chronic data for RVT-3101 in ulcerative colitis, efficacy improved from induction at week 56
--------------------------------------------------------------------------------

- At expected Phase 3 dose, Clinical Remission 36% at week 56 vs 29% at week 14; Endoscopic Improvement 50% vs 36%.
- In biomarker-positive patients, Clinical Remission 43% at week 56 (33% at week 14), Endoscopic Improvement 64% (47%).
- Favorable safety profile through 56 weeks; 0% neutralizing antibodies at week 56 at Phase 3 dose.
- First long-duration data for an anti-TL1A antibody; results support Phase 3 potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123030856/0001140361-23-030856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123030856/brhc20054731_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-030856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer